FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Algernon Scales up Manufacturing of NP-120 (Ifenprodil) to Prepare for Coronavirus and Acute Lung Injury US Clinical Trials”
Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) (CSE: AGN) (FRANKFURT: AGW) a clinical stage pharmaceutical development company is pleased to announce that it has made the decision to begin production of NP-120 (Ifenprodil) with a new injectable and long acting oral release formulation, in order to be prepared for new US clinical trials for COVID-19 (coronavirus) and acute lung injury (ALI).
Algernon Pharmaceuticals is a clinical stage pharmaceutical development company focused on advancing its lead compounds for non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF), and chronic cough.
The 2019 outbreak of a coronavirus (COVID-19), which used to be called the novel coronavirus (2019-nCoV), represents a new type of coronavirus. It causes respiratory illness and was first diagnosed in Wuhan, China. The COVID-19 can spread from person to person, and usually travels through respiratory droplets expelled by coughs or sneezes. There are several different types of coronaviruses that can infect humans, including the COVID-19, the Middle East respiratory syndrome (MERS) and the severe acute respiratory syndrome (SARS) coronaviruses. As of March 4th, the Centers for Disease Control and Prevention (CDC) reported at least 80 confirmed cases of COVID-19 in the U.S, along with nine deaths in Washington state. Furthermore, among the 13 states where the virus is found, California is now in the center of attention. According to a report by NPR, Los Angeles declared a health emergency due to the coronavirus on Wednesday, citing the need to address the possibility of community transmission of the disease that has caused more than 3,200 deaths globally. However, the CDC expects more cases to be detected across the country as the outbreak of COVID-19 continues to expand and testing capacity in the U.S. increases. And while information so far suggests that most COVID-19 illnesses are mild, a report out of China suggests serious illness occurs in 16% of cases.
In response to the outbreak, governments around the world have focused their resources on curing COVID-19. Besides the research necessary to develop a vaccine, accelerated R&D also focuses on diagnostic techniques, specifically on the scope of blood testing services throughout the industry. For example, researchers around the world are racing to develop antibody tests, also called serological tests, that can confirm whether someone was infected even after their immune system has cleared the virus. According to a report published by American Association for the Advancement of Science (AAAS), disease trackers in Singapore have used an experimental antibody test for COVID-19 to confirm that a suspected patient was infected with the coronavirus. The patient was one of two people who together formed a missing link between two clusters of cases that each occurred in a Singaporean church. “The group that developed the test, at Duke-NUS Medical School in Singapore, is among the front-runners, although its assay has to be validated before it is taken into production and deployed widely. In blood samples from recovered patients, the team identified antibodies targeting the spike protein that proved able to block the virus from killing cells in laboratory tests. In parallel, they created synthetic viral proteins that can detect those antibodies in a blood sample without having to use the live virus,” AAAS explains.
For more information, please visit: Algernon Pharmaceuticals Inc.
For more corporate news on Algernon Pharmaceuticals Inc., check out the Buzz on the Street
About Buzz on the Street: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.